Navigation Links
Statins may Help Treat Hepatitis C Patients

A new study has demonstrated the potential of statins, used in important cholesterol management therapies, for improving the management of hepatitis C .

Statins or HMG-CoA reductase inhibitors form a class of hypolipidemic agents, used as pharmaceutical agents to lower cholesterol levels in people with or at risk for cardiovascular disease.

Two studies were conducted by a team of researchers led by Ted Bader at the University of Oklahoma in Oklahoma City to see the effect of statins.

As part of the first study, researchers conducted a 14-day study looking at the antiviral effect of fluvastatin (FLV) in vivo, in hepatitis C virus (HCV) patients who take statins, to see whether they experience any improvements in alanine transaminase (ALT, liver enzymes) levels.

The researchers reported the total bilirubin (TB, yellow breakdown product) and ALT results and compared the findings to an existing hepatitis C registry data.

Researchers found that three patients with abnormal ALTs at baseline experienced significant improvement and nine patients who started with normal ALTs stayed normal.

In addition, there were no significant changes in TB levels. No liver problems were noted despite FLV doses that were up to four times the highest FDA-approved dose.

Scientists also examined the existing HCV registry and noted both the number of patients who improved their abnormal ALT levels after statin therapy and the number of patients who maintained their normal ALT levels after initiation of statin therapy. Of the abnormal ALT group, 12 had improved ALT and one stayed unchanged. Of the 47 beginning in the normal range, 45 maintained their ALTs.

"This is the first report of prospectively using fluvastatin in HCV patients. Two remarkable observations were made and data not only supports the lack of harm in this situation, but also seems to suggest a possible salutary effect t hat needs further study," Bader said.

As part of naother study researchers retrospectively analyzed the effect of taking peginterferon and ribavirin (PI+R, hepatitis C treatment options) and PI+R plus a statin to measure the sustained viral response (SVR, negative virus in blood six months after the end of treatment) rate in hepatitis C patients.

In this study, 104 patients taking PI+R were compared to 30 patients who took PI+R plus a statin. Almost all patients (25 of the 30) taking a statin were on simvastatin, two were on lovastatin, two were on atorvastatin and one on fluvastatin.

Researchers found that the patients on standard treatment achieved a 37 percent SVR rate, the highest SVR reported to date in the medical literature for a VA-based population.

Having a high SVR rate means a cure is 95 percent of the time based upon long-term follow up that is greater than six months after treatment. The SVR rate for patients taking triple therapy, PI+R plus a statin, was 63 percent.

"It is important for statins to be studied prospectively for their effect on hepatitis C. Further study may contribute to developing a more effective outcome of treatment," Bader said.


'"/>




Related medicine news :

1. Statins reduce heart attacks
2. Statins reduce risks for angioplasty patients
3. Statins Found To Be Helpful For Patients With Arthritis
4. Long-Term Benefits Of Statins Questioned
5. Statins Not Effective In Treating Calcific Aortic Stenosis
6. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
7. The Effects of Statins Questioned
8. Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well
9. Study Finds No Link Between Statins And Breast Cancer Risk
10. Statins Reduce Deaths And Strokes After Carotid Surgery
11. Statins reduces cardiovascular risk but no cancer risk.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... MA (PRWEB) , ... April 29, 2016 , ... ... the Two Ten Footwear Foundation, the national charitable foundation serving the footwear industry, ... With 8,000 volunteers representing more than 130 companies across 23 states during the ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Spiritual Awakening , announces the addition Onnit brand Alpha BRAIN and New Mood ... of Onnit brain and mood optimization products to the store is just one ...
(Date:4/29/2016)... ... , ... On Tuesday, April 26, 2016 members of the HomeTown Health network, ... Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, ... credit to individuals and corporations which donate directly to a “rural hospital” in Georgia, ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... ... ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite Back ... light breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers participated ... and 1-mile walk were held to increase awareness about Lyme disease and to raise ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
(Date:4/28/2016)... 2016  ValGenesis, Inc., the market leader ... today announced that a prominent world provider ... chronic kidney failure has selected ValGenesis Validation ... validation process. The global medical device manufacturer ... manage their validation processes electronically. Upon completion ...
Breaking Medicine Technology: